Sermorelin is the shorter-acting, FDA-precedent GHRH analog; CJC-1295 (especially with DAC) is the longer-acting, research-chemistry cousin. Sermorelin is the conservative clinical choice; CJC-1295 is the research choice when you want sustained GH-axis tone with less frequent injections.
| CJC-1295 | Sermorelin | |
|---|---|---|
| Class | GHRH analog (growth-hormone-releasing hormone) | Growth hormone-releasing hormone analog (GHRH 1-29) |
| Half-life | No-DAC: ~30 minutes. DAC version: ~6–8 days. | Approximately 10–20 minutes |
| Typical dose | 100 mcg, 1–3x daily (no-DAC); 1–2 mg weekly (DAC) | 100–500 mcg per injection, typically at bedtime 5 days per week |
| Category | Growth hormone axis | GH secretagogue (GHRH) |
| FDA status | Not FDA approved. Research use only. | Previously FDA approved for pediatric GH deficiency (withdrawn in 2008 for commercial reasons, not safety). Widely compounded. |
| Storage | Lyophilized refrigerated. | Lyophilized refrigerated. |
Both are GHRH-receptor agonists that stimulate pituitary GH release. Both act upstream of the pituitary rather than replacing GH directly. Both are typically combined with a GHRP (like Ipamorelin) for a physiological GH pulse.
Pick CJC-1295 when you want sustained GHRH tone without daily injections. With-DAC CJC-1295 extends the half-life to several days via albumin binding — a few injections per week instead of daily. Without-DAC CJC-1295 (mod-GRF 1-29) is closer to Sermorelin in kinetics but with subtle structural stabilization.
Pick Sermorelin when you want the compound with the deepest clinical history. Sermorelin was FDA approved (as Geref) and has been used in pediatric GH-deficiency and adult anti-aging protocols for decades. Short half-life means a cleaner physiological pulse with less receptor-saturation risk.
No — they are both GHRH analogs; using both adds no mechanism. Pick one as your GHRH input and pair it with a GHRP.
Peptide Protocol schedules doses, calculates reconstitution, and logs side effects for both — on iPhone, free to download.
See the app →CJC-1295 with DAC has a half-life of days; Sermorelin has a half-life of ~10–20 minutes. That is the entire choice — sustained tone (CJC-DAC) vs pulsatile physiological signal (Sermorelin).
No — they are both GHRH analogs; using both adds no mechanism. Pick one as your GHRH input and pair it with a GHRP.
Sermorelin is the shorter-acting, FDA-precedent GHRH analog; CJC-1295 (especially with DAC) is the longer-acting, research-chemistry cousin. Sermorelin is the conservative clinical choice; CJC-1295 is the research choice when you want sustained GH-axis tone with less frequent injections.
Pick CJC-1295 when you want sustained GHRH tone without daily injections. With-DAC CJC-1295 extends the half-life to several days via albumin binding — a few injections per week instead of daily. Without-DAC CJC-1295 (mod-GRF 1-29) is closer to Sermorelin in kinetics but with subtle structural stabilization.
Pick Sermorelin when you want the compound with the deepest clinical history. Sermorelin was FDA approved (as Geref) and has been used in pediatric GH-deficiency and adult anti-aging protocols for decades. Short half-life means a cleaner physiological pulse with less receptor-saturation risk.
CJC-1295: Not FDA approved. Research use only. — Sermorelin: Previously FDA approved for pediatric GH deficiency (withdrawn in 2008 for commercial reasons, not safety). Widely compounded.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.